Subsequently, we stratified the LUAD patient samples based on the expression of these 16 TSGs and found that high expression of these genes is collectively predictive of positive outcomes in KRAS mutant lung cancer patients, but not in patients with KRAS wild-type tumors (Fig. 8d). This evidence concerns the gene KRAS and lung carcinoma.